[MO32] Mini-Oral Session 32　臨床試験推進プログラム2
【E】

[MO32-4] Cost-effectiveness of SLOG vs mFOLFIRINOX as the First-line Treatment in Metastatic Pancreatic Ductal Adenocarcinoma

^○Yi-Hsin Yang¹, Chen-Hao Wu¹, Nai-Jung Chiang¹, Yan-Shen Shan², Li-Yuan Bai⁴, Chung-Pin Li⁵, Jen-Shi Chen⁶, Li-Tzong Chen^1,3 (1.National Institute of Cancer Research, National Health Research Institutes, Taiwan, 2.National Cheng Kung University, Taiwan, 3.Kaohsiung Medical University Hospital, Taiwan, 4.China Medical University Hospital, Taiwan, 5.Taipei Veterans General Hospital, Taiwan, 6.Linkou Chang Gung Memorial Hospital, Taiwan)